The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy
In this video, Jonas Paludo, MD, Mayo Clinic, Rochester, MN, discusses the challenges and management of adverse events (AEs) related to CAR-T therapy, including cytokine release syndrome (CRS) and neurotoxicity. Dr Paludo first comments on how the management of CRS has improved over the years, and then goes on to discuss treatment options for patients who progress after CAR-T therapy, including bispecific antibodies and antibody-drug conjugates (ADCs). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm and Biofourmis – both research funding to my institution
